Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: There are limited clinical data on drug-coated balloon (DCB)-based percutaneous coronary intervention (PCI) compared with drug-eluting stent (DES)-only PCI in patients with complex coronary artery lesions.
Objectives: The goal of the current study was to investigate the efficacy of DCB in patients undergoing PCI for complex coronary artery lesions.
Methods: From an institutional registry of patients with de novo complex coronary artery lesions, 126 patients treated with DCB-based PCI were compared with 234 propensity score-matched patients treated with DES-only PCI. Complex coronary artery lesions were defined as the presence of at least 1 of the following: bifurcation, chronic total occlusion, unprotected left main disease, long lesion ≥38 mm, multivessel disease, lesion requiring ≥3 devices, or severe calcification. The primary endpoint was target vessel failure (TVF) at 2 years, a composite of cardiac death, target vessel-related myocardial infarction, and target vessel revascularization.
Results: Baseline characteristics were comparable between the 2 groups. DCB-based PCI showed a comparable risk of TVF vs DES-based PCI (7.6% vs 8.1%; HR: 0.81; 95% CI: 0.33-1.99; = 0.638). The risks of cardiac death (5.0% vs 5.7%; HR: 0.78; 95% CI: 0.24-2.49), target vessel-related myocardial infarction (0.9% vs 1.3%; HR: 2.65; 95% CI: 0.26-27.06), and target vessel revascularization (3.5% vs 2.0%; HR: 1.30; 95% CI: 0.30-5.67) were also comparable between the 2 groups.
Conclusions: DCB-based PCI showed comparable risks of TVF vs those of DES-only PCI in patients with complex coronary artery lesions. DCB might be considered as a suitable alternative device to DES in patients undergoing complex PCI. (Long-term Outcomes and Prognostic Factors in Patient Undergoing CABG or PCI; NCT03870815).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291392 | PMC |
| http://dx.doi.org/10.1016/j.jacasi.2024.04.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.
Heart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDFA tale of two tracers - Amyloid imaging with investigational radiotracers iodine (I) evuzamitide and Tc-p5+14 (AT-05).
J Nucl Cardiol
August 2025
Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA.
Systemic amyloidosis is a complex disorder, making early and accurate diagnosis challenging. The most common types are associated with misfolded transthyretin or immunoglobulin light chains, where cardiac and renal amyloidosis portend the worst prognosis. Peptide p5+14 can bind all types of amyloid via multivalent electrostatic interactions.
View Article and Find Full Text PDFArtificial intelligence in HFpEF: Diagnosis, prognosis, and management strategies.
J Cardiol
September 2025
Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Cardiology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic addr
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of all HF cases and its incidence and prevalence continue to increase, with a substantial burden of morbidity and mortality. Despite advances in our understanding of heterogeneous pathophysiology underlying HFpEF, the diagnosis, risk assessment, and management of this disease entity remain challenging in everyday practice. Artificial intelligence (AI) algorithm can handle large amounts of complex data and machine learning (ML), a subfield of AI, allows for the identification of relevant patterns by learning from big data.
View Article and Find Full Text PDFObesity in Cardiac Rehabilitation: Considerations in Offering Weight Management as Part of Cardiac Rehabilitation Programs.
Can J Cardiol
September 2025
TotalCardiology Research Network, Calgary, AB; Department of Psychology, University of Regina, SK.
Despite its relevance to cardiovascular health, obesity is rarely targeted during cardiac rehabilitation (CR). The objective of this paper was to review evidence regarding whether measures to address excess body fat should be offered as a standard component of CR for patients with obesity. We organize the paper around three themes: 1) outcomes of obesity management, 2) the complexity of obesity management, and 3) patient attitudes, experiences, and preferences.
View Article and Find Full Text PDFReliable and sensitive ultra-short chain per- and polyfluorinated alkyl substances (PFAS) analysis in food: a polar reverse-phase chromatography approach.
J Chromatogr A
September 2025
Istituto Nazionale di Ricerca Metrologica (INRIM), Strada delle cacce 91, Turin, 10135, Italy.
Food contamination by per- and polyfluoroalkyl substances (PFAS), especially ultra-short-chain (USC) compounds, poses a growing concern due to their environmental persistence and potential health risks. Despite the developing regulatory framework, analytical challenges persist in quantifying polar USC-PFAS in complex content food matrices. This study presents the development and validation of a novel high-performance liquid chromatography coupled to a tandem mass spectrometer (HPLC-MS/MS) method for the accurate determination of USC-PFAS (carbon chain length from one to four, C1-C4) in tomato-based products (i.
View Article and Find Full Text PDF